Diagnosis and treatment of hypereosinophilic syndromes

Current Opinion in Hematology

Volumn 14, Issue 1, 2007, Pages 37-42

  Fletcher, Sarah ^a   Bain, Barbara ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Eosinophilia; Eosinophilic leukemia; Hypereosinophilic syndromes; Tyrosine kinase inhibitors

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BUSULFAN; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; ETOPOSIDE; HYDROXYUREA; IMATINIB; INTERLEUKIN 5 ANTIBODY; MERCAPTOPURINE; METHOTREXATE; MIDOSTAURIN; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; SORAFENIB; STEROID; TIOGUANINE; VINCRISTINE;

ALLOGRAFT; CLONAL VARIATION; CYTOGENETICS; CYTOKINE RELEASE; DECISION MAKING; DIAGNOSTIC TEST; DRUG BINDING SITE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; GENE; GENE MUTATION; GENE REARRANGEMENT; GENETIC DISORDER; HUMAN; HYPEREOSINOPHILIC SYNDROME; LOW DRUG DOSE; MOLECULAR GENETICS; OPTIMAL DRUG DOSE; PDGFRA GENE; PDGFRB GENE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEROID THERAPY; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

EID: 33845371475     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/00062752-200701000-00008     Document Type: Review

References (33)

1. Tefferi A, Gilliland G. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Best Practice & Research Clinical Haematology 2006; 19:365-385.
2. Bain BJ. Quantitative changes in blood cells. In: Blood cells: a practical guide. 3rd ed. Oxford: Blackwell Science Limited; 2002. pp. 192-196.
3. Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of interleukin-5-producing T cells in idiopathic eosinophilia. N Engl J Med 1999; 341:1112-1120.
4. Bain B, Pierre R, Imbert M, et al. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours; Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. pp. 29-31.
5. Fletcher S, Abdalla S, Edwards M, Bain B. Teaching cases, case 32: Eosinophilia: reactive or neoplastic? Leuk Lymphoma (in press).
6. Gotlib J, Cross NCP, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 2006; 19:535-569. This is an excellent review, especially for further detail regarding molecular aspects of eosinophilic leukemia.
7. Tanaka Y, Kurata M, Toqami K, et al. Chronic eosinophilic leukaemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy. Int J Hematol 2006; 83:152-155. This is the first report of possible therapy-related FIP1L1-PDGFRA fusion.
8. Robyn J, Lemery S, McCoy JP, et al. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 2005; 132:286-292. An important paper, looking at which lineages are involved in the FIP1L1-PDGFRA fusion-forming mutation.
9. Bain BJ. Relationship between the idiopathic hypereosinophilic syndrome, eosinophilic leukaemia and systemic mastocytosis. Am J Hematol 2004; 77:82-85.
10. Baxter EJ, Hochhaus A, Bolufer P, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002; 11:1391-1397.
11. Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20:827-832. This is an example of a new fusion gene involving DGFRA.
12. Walz C, Curtis C, Schnittger S, et al. Transient response to imatinib in a chronic eosinophilic leukaemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006; Jul 14 [Epub ahead of print].
13. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemia. Br J Haematol 2003; 122:173-179.
14. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106:2162-2168.
15. Chung KF, Hew M, Score J, et al. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. Eur Respir J 2006; 27:230-232.
16. Bain BJ. The idiopathic hypereosinophilic syndrome and eosinophilic leukemias. Haematologica 2004; 89:238-239.
17. Pardanani A, Ketterling RP, Li C-Y, et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30:965-970. This is a useful review, particularly with respect to imatinib therapy.
18. Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. J Allergy Clin Immunol 2006; 117:1292-1302. This is an important report from a consensus-forming meeting of world-experts in eosinophilic syndromes.
19. Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102:3456-3457.
20. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes is a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201-1214.
21. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell 2003; 3:459-469.
22. Lierman E, Folens C, Stover EH, et al. Sorafenib (BAY43-9006) is a potent inhibitor of FIP1L1-PDGFRa and the imatinib resistant FIP1L1-PDGFRα T674I mutant. Blood 2006; Apr 27 [Epub ahead of print]. This interesting report shows that an alternative tyrosine kinase inhibitor can overcome the mutation conferring imatinib resistance in FIP1L1-PDGFRA positive eosinophilic leukemia.
23. Robert C, Delva L, Balitrand N, et al. Apoptosis induction by retinoids in eosinophilic leukemia cells: Implication of retinoic acid receptor-α signalling in All-trans-retinoic acid hypersensitivity. Cancer Res 2006; 66:6336-6344. This potentially important paper may show a new use for all-trans-retinoic acid.
24. Chen J, DeAngelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Sci USA 2004; 101:14479-14484.
25. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006; 133:468-492. This is a very good review of many aspects of eosinophilia.
26. Ceretelli S, Capochiani E, Petrini M. Interferon-a in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol 1998; 77:161-164.
27. Schandene L, Roufosse F, de Lavareille A, et al. Interferon a prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood 2000; 96:4285-4292.
28. Müller AMS, Martens UM, Hofmann SC, et al. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 2006; 85:1-16. This is another good review regarding imatinib in CEL.
29. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 2005; 114:52-60.
30. Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004; 127:477.
31. Sefcick A, Sowter D, DasGupta E, et al. Alemtuzumab therapy for refractory hypereosinophilic syndrome. Br J Haematol 2004; 124:558-559.
32. Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal antiinterleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004; 103:2939-2941.
33. Cooper MA, Akard LP, Thompson JM, et al. Hypereosinophilic syndrome: Long term remission following allogeneic stem cell transplant in spite of transient eosinophilia posttransplant. Am J Hematol 2005; 78:33-36.